Scopus BioPharma to Reschedule 2021 Annual Meeting of Shareholders
May 26 2021 - 7:30PM
Scopus BioPharma Inc. (Nasdaq:
“SCPS”) today announced it will be rescheduling the
company’s 2021 Annual Meeting of Shareholders (the “2021 Annual
Meeting”), which was previously scheduled for July 16, 2021. Once
determined by the Scopus Board of Directors, the company will
announce the new date, time and location of the 2021 Annual
Meeting.
About Scopus BioPharma
Scopus BioPharma Inc. is a biopharmaceutical
company developing transformational therapeutics capitalizing on
groundbreaking scientific and medical discoveries from leading
research and academic institutions. The company’s lead drug
candidate is a novel, targeted immuno-oncology RNA therapy for the
treatment of multiple cancers. This drug candidate is highly
distinctive, encompassing both RNA therapy and immunotherapy by
synthetically linking siRNA to an oligonucleotide TLR9 agonist,
creating the potential for targeted gene silencing with
simultaneous TLR stimulation and immune activation in the tumor
microenvironment. The company is also developing additional new
chemical entities to treat other serious diseases with significant
unmet medical needs, including systemic sclerosis. Receive updates
by following Scopus BioPharma on Twitter here.
Forward-Looking Statements
This press release may include forward-looking
statements that involve risks and uncertainties. Forward-looking
statements are statements that are not historical facts. Such
forward-looking statements are subject to risks (including those
set forth in the company’s offering circular filed with the U.S.
Securities and Exchange Commission (“SEC”)) and uncertainties which
could cause actual results to differ from the forward-looking
statements. The company expressly disclaims any obligations or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in the company’s expectations with respect thereto or any change in
events, conditions or circumstances on which any statement is
based. Investors should realize that if our underlying assumptions
for the projections contained herein prove inaccurate or that known
or unknown risks or uncertainties materialize, actual results could
vary materially from our expectations and projections.
Important Additional Information and
Where to Find It
Scopus Biopharma Inc. plans to file a proxy
statement (the “Proxy Statement”) with the SEC in connection with
the solicitation of proxies for the 2021 Annual Meeting, together
with a WHITE proxy card. STOCKHOLDERS ARE URGED TO READ THE PROXY
STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY
OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC
CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE
THEY WILL CONTAIN IMPORTANT INFORMATION.
Stockholders will be able to obtain, free of
charge, copies of the Proxy Statement, any amendments or
supplements thereto and any other documents (including the WHITE
proxy card) when filed by the company with the SEC in connection
with the 2021 Annual Meeting at the SEC’s website
(https://www.sec.gov), at the company’s website
(https://scopusbiopharma.com) or by contacting the company’s proxy
solicitor, Morrow Sodali, at (203) 658-9400 or, by e-mail, at
SCPS@investor.morrowsodali.com.
Participants in the
Solicitation
The company, its directors and certain of its
executive officers and other employees may be deemed to be
participants in the solicitation of proxies from stockholders in
connection with the 2021 Annual Meeting. Additional information
regarding the identity of these potential participants, none of
whom (other than Ira Scott Greenspan, Joshua R. Lamstein, Paul E.
Hopper, Ashish P. Sanghrajka and Robert J. Gibson) owns in excess
of one percent (1%) of the company’s voting shares, and their
direct or indirect interests, by security holdings or otherwise,
will be set forth in the Proxy Statement and other materials to be
filed with the SEC in connection with the 2021 Annual Meeting.
Information relating to the foregoing can also be found in the
company’s Form 10-K/A, filed with the SEC on April 29, 2021. To the
extent holdings of the company’s securities by such potential
participants (or the identity of such participants) have changed
since the information printed in the Form 10-K/A, such information
has been or will be reflected on Statements of Change in Ownership
on Forms 3 and 4 filed with the SEC. You may obtain free copies of
these documents using the sources indicated above.
Contacts
Rodd Leeds/David WaldmanCrescendo
Communications, LLCTel: (212) 671-1020Email:
SCPS@crescendo-ir.com
Hugh Burns/Delia Cannan/Nicholas Leasure
ReevemarkTel: (212) 433-4600Email: scopus@reevemark.com
Shareholders Contact
Mike Verrechia/Bill DooleyMorrow Sodali, LLCTel:
(203) 658-9400Email: SCPS@investor.morrowsodali.com
Scopus BioPharma (NASDAQ:SCPS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scopus BioPharma (NASDAQ:SCPS)
Historical Stock Chart
From Jul 2023 to Jul 2024